OOIR: Observatory of International Research

Papers

(The TQCC of Leukemia Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Editorial Board	59
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling	35
Acquired alpha thalassemia associated with myeloid malignancy: A systematic literature review	34
Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia	30
Editorial Board	24
DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma	21
Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)	19
SOX11 AND EPSTEIN–BARR VIRUS MAY SUBSTITUTE EACH OTHER IN EARLY PATHOGENESIS OF BURKITT LYMPHOMA	17
TARGETED THERAPY INCREASES PD-L1 PROTEIN EXPRESSION IN CELL LINES OF MEDIASTINAL LYMPHOMA	17
ASSEMBLING A RARE NON-HODGKIN LYMPHOMA COHORT: EARLY FINDINGS FROM “THE UMBRELLA STUDY”	16
Exploring the pathogenesis of extranodal natural killer/T cell lymphoma complicated With EBV via microarray data analysis	16
DONOR-DERIVED B-LYMPHOBLASTIC LYMPHOMA FOLLOWING RENAL TRANSPLANT: A CASE REPORT	16
Topic: AS01-Diagnosis/AS01a-Cytomorphology: ARTIFICIAL INTELLIGENCE MAY HELP THE HEMATOPATHOLOGIST IN EVALUATION OF BONE MASS AND CELLULARITY IN BONE MARROW SPECIMENS OF PATIENTS WITH MDS	15
EFFICACY AND SAFETY OF SEQUENTIAL DIFFERENT B CELL ANTIGEN-TARGETED CAR T-CELL THERAPY FOR PEDIATRIC REFRACTORY/ RELAPSED BURKITT LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT	15
5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES	15
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: HIGHER LEPTIN LEVEL IS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME: A COMPARATIVE STUDY	15
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA	15
Changing frontline AML treatment patterns from 2013 to 2022	15
MDS AND AUTO-IMMUNITY	14
Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy	14
How low can you go?: Methodologic considerations in clonal hematopoiesis variant calling	14
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)	14
CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES	14
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES TH	14
DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING	14

MDSF - EHA JOINT SESSION	13
Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis	13
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART I	13
THE TITO BASTIANELLO AND MDSF YOUNG INVESTIGATORS AWARDS	13
Pathogenic mechanisms and targeted therapies for anemia in myelodysplastic syndromes	12
A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation	12
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group	12
ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT	12
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols	11
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia	11
Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study	11
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis	11
PROGNOSIS - PROGNOSTIC FACTORS OF OUTCOME AND RISK ASSESSMENT	11
Editorial Board	11
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION	10
GUIDED POSTER VIEWING SESSION 2: FUNDAMENTAL	10
DIAGNOSIS - CYTOMORPHOLOGY AND HISTOLOGY	10
Roles of noncoding RNAs in multiple myeloma	10
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART II	10
A RARE CASE OF PRIMARY OCULAR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN A BRAZILIAN CHILD	10
MDS BIOLOGY AND PATHOGENESIS - CLONAL DIVERSITY & EVOLUTION	10
MCL-1 INHIBITORS INDUCES APOPTOSIS IN VITRO IN BURKITT LYMPHOMA CELL LINES AND INHIBITS IN VIVO BURKITT LYMPHOMA PROGRESSION	9
ACCELERATED RNA SPLICING DYNAMICS DURING ERYTHROID DIFFERENTIATION AMPLIFY MIS-SPLICING IN SF3B1-MUTANT MDS-RS	9
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis	9
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML	9
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCREASED DNA-CELL-CYCLE S-PHASE FRACTION IS RELATED TO INCREASED INCIDENCES OF IMMATURE MYELOID CELLS AND HIGH IPSS-R RI	9
Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia	9
IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL	9
Topic: AS09-Quality of life-Disease experiences: ANEMIA OF CHRONIC DISEASE IN THE ELDERLY: EVALUATION OF HEPCIDIN EXPRESSION AND ITS RELATIONSHIP WITH PROINFLAMMATORY CYTOKINES AND CLINICAL AND LABORA	9
FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY	9
PRE-TRANSPLANT TREATMENT OF HEPATISPLENIC T-CELL LYMPHOMA (GAMMA-DELATA): A PEDIATRIC CASE REPORT	8
EXTRACELLULAR VESICLES AS KEY ORCHESTRATORS OF BONE MARROW NICHE REMODELING IN PEDIATRIC MATURE-B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	8
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation	8
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies	8
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis	8
FDG-PET/CT IMAGING IN PEDIATRIC PRECURSOR B-CELL LYMPHOBLASTIC LYMPHOMA (BCP-LBL) SHOWS BONE (MARROW) INVOLVEMENT IN A VAST MAJORITY OF PATIENTS	8
MicroRNAS DOWNREGULATE TUMOR SUPPRESSOR GRK2 IN MALT1-DEPENDENT DIFFUSE LARGE B-CELL LYMPHOMA	8
ALK+ ALCL EVADES IMMUNE SURVEILLANCE THROUGH NPM-ALK-DRIVEN EPIGENETIC REPRESSION OF Cd48	8
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia	8
Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute lymphoblastic leukemia pediatric patients with high‑risk first‑relapse in Mexico	8
IS TRANSCRIPTIONAL CELL STATE THE KEY TO PREDICTING RESISTANCE IN BURKITT LYMPHOMA?	8
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) P	8
CIRCULATING TUMOR DNA IN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: A PROOF-OF-CONCEPT STUDY	8
Identification of ZNF384 as a regulator of epigenome in leukemia	8
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy	8
Cutaneous manifestations of large granular lymphocytic leukemia: A case report and systematic review	8
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: INTEGRATED ANALYSIS OF MDS-OMICS INFORMS ON DRUG RESPONSE PROFILES	7
THE TCRB REPERTOIRE IN PEDIATRIC ALK-POSITIVE ALCL	7
RAPID FIRE SESSION 01	7
MiR-409–3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10	7

ADVANCES IN PEDIATRIC LYMPHOBLASTIC LYMPHOMA: DEMOGRAPHIC CLINICAL CHARACTERISTICS, TREATMENT AND LONG-TERM OUTCOME: INSTITUTIONAL EXPERIENCE OVER 30 YEARS	7
Impact of the quantity and quality of the skeletal muscle on survival among patients undergoing allogeneic hematopoietic stem cell transplantation	7
VARIANT ALK-FUSION POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): A POPULATION-BASED COHORT OF THE NHL-BFM STUDY GROUP	7
Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia	7
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: PREVALENCE, DYNAMICS AND CLINICAL SIGNIFICANCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN NEWLY DIAGNOSED CANCER PATIEN	7
Health system costs and autologous stem cell transplant receipt for participants with multiple myeloma in the Australian 45 and Up Study	7
PARALLEL SESSION 01: TP53 IN MDS	7
IMPROVING GLOBAL TREATMENT OUTCOMES OF CHILDREN DIAGNOSED WITH BURKITT LYMPHOMA	7
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia	7
Editorial Board	7
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: SECONDARY FINDINGS IN EXOME SEQUENCING IN 240 EARLY-ONSET ADULT MYELODYSPLASTIC SYNDROMES WITHOUT PREVIO	7
Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms	7
RAPID FIRE SESSION 01	7
Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvem	7
DIAGNOSIS - MOLECULAR ABERRATIONS (CYTOGENETIC, GENETIC, GENE EXPRESSION)	7
RAPID FIRE SESSION 02	7
Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture	7
Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing	7
Topic: AS01-Diagnosis/AS01b-Flow cytometry: IMMUNOPHENOTYPIC BONE MARROW CHARACTERISTICS IN MYELODYPLASTIC SYNDROME WITH SF3B1 MUTATION	7
LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma	6
CLINICAL, HISTOLOGICAL, AND GENETIC CHARACTERIZATION OF AGGRESSIVE B-CELL LYMPHOPROLIFERATIONS IN PATIENTS WITH INBORN ERRRORS OF IMMUNITY	6
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience	6
PRINCIPAL ACTIONS OF THE MYELODYSPLASTIC SYNDROME HSCT AMERICAN LATIN REGISTRY	6
BONE MARROW INFILTRATION AS A PROGNOSTICE FACTOR IN PEDIATARIC BURKITT LYMPHOMA PATIENTS	6
PLENARY SESSION 05: MDS CLASSIFICATION IN 2025	6
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART I	6
Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL	6
CURRENT CARDIOVASCULAR DISEASE (CVD) RISK PREDICTION MODELS ARE NOT APPLICABLE IN MDS PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY	6
Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis	6
Assessing the associations of blood metabolites with myelodysplastic syndrome: A bidirectional mendelian randomization study	6
Corrigendum to “Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy” [Leuk. Res. 122 (2022) 106949]	6
18F-FDG-PET/CT IN THE ASSESSMENT OF BONE MARROW INVOLVEMENT IN PEDIATRIC NON-HODGKIN LYMPHOMA- A SINGLE CENTER EXPEREIENCE	6
PI3K/AKT inhibitor BEZ-235 targets CCND2 and induces G1 arrest in breast implant-associated anaplastic large cell lymphoma	6
PARALLEL SESSION 05: PREDICTIVE MODELS FOR RESPONSE IN HIGH RISK MDS	6
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study	6
Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series	6
PARALLEL SESSION 04: PREDICTIVE MODELS FOR RESPONSE IN LOW RISK MDS	6
Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience	6
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN LOWER-RISK MDS TRANSFUSION-DEPENDENT PATIENTS; A SINGLE-CENTRE EXPERIENCE	6
BCL2 FAMILY INHIBITORS	6
THE CHALLENGE OF PROSPECTIVE DISTINCTION BETWEEN NON-NEOPLASTIC VERUS NEOPLASTIC EBV-ASSOCIATED HLH	6
PEDIATRIC LOW GRADE LYMPHOMAS: A REPORT FROM A SINGLE CENTRE	6
TREATMENT - CURRENT TREATMENT OPTIONS - HIGHER RISK MDS	6
TREATMENT - NEW DEVELOPMENTS - PRECLINICAL STUDIES	6
PYRIMETHAMINE, A STAT3 INHIBITOR, HAS SYNERGY WITH VENETOCLAX AND IS EFFICACIOUS IN HYPOMETHYLATING AGENT RESISTANT MDS/AML	6
Topic: AS01-Diagnosis/AS01a-Cytomorphology: DIAGNOSTIC CHALLENGE BETWEEN WHO AND ICC CLASSIFICATION	6
Universal posttransplant cyclophosphamide after allogeneic transplant, a retrospective single institution study	5
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITID	5
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation – Post-transplantation treatment: IN VIVO DUAL T CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME	5
ENHANCING CD20.CAR NK CELL THERAPY IN RITUXIMAB-RESISTANT BURKITT LYMPHOMA USING IL-15-BASED IMMUNOMODULATORS WITH NKTR-255 OR ANTI-CD16-IL15-ANTI-CD19 TRIKE	5
Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults	5
Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: VENETOCLAX AND AZACYTIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES, A REAL-WORLD EXPERIENCE. LATIN-AMERICAN MDS GROUP – GLAM	5
Philadelphia-positive B-lymphoblastic leukemia in a middle-income country – A real-world multicenter cohort	5
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study	5
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123	5
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity	5
Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei	5
IMMUNOGLOBULIN SUBCLASSES OF ANTI-ALK ANTIBODIES IN PEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA	5
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: MUTATION-SPECIFIC HSPC ENRICHMENT PATTERNS UNDERLIE PROGNOSTICALLY SIGNIFICANT TRANSCRIPTOMIC SUBGROUPS OF MDS PATIENTS	5
NPM::ALK TRANSCRIPT LEVELS AND ANTI-ALK AUTOANTIBODY TITERS AS BIOMARKERS FOR OUTCOME IN PEDIATRIC ALK+ ANAPLASTIC LARGE CELL LYMPHOMA TREATED WITH BRENTUXIMAB VEDOTIN OR CRIZOTINIB IN COMBINATION WIT	5
ANALYSIS OF THE CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS OF MULTICENTER CHILDHOOD BURKITT LEUKEMIA	5
PEDIATRIC NON-HODGKIN LYMPHOMA IN THE TURKISH PEDIATRIC CANCER REGISTRY (2009–2024) (TPOG & TPHD DATA)	5
Retraction notice to “Low-dose radiotherapy (2×2 g) versus low doses and rituximab in the treatment of marginal zone b-cell lymphoma previously untreated” [Leuk. Res. 98C (2020) 106443]	5
Therapeutic advances for the management of adult T cell leukemia: Where do we stand?	5
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT FOR PATIENTS WITH LOWER RISK MDS ADMITTED TO THE HEMATOLOGY DEPARTMENT OF THE COLENTINA CLINICAL HOSPITAL - DATA FR	5
Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement	5
Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study	5
Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines	5
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias	5
QOL	5
RARE CASE OF COMPOSITE LYMPHOMA IN ADOLESCENT PATIENT – DIAGNOSTIC AND TREATMENT CHALLENGES	5
GERMLINE VARIANTS OF PIK3CD AND PIK3R1 IN PEDIATRIC NON-HODGKIN LYMPHOMA: INSIGHTS INTO THE ROLE OF APDS-ASSOCIATED ALTERATIONS	5
Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL)	5
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?	5
SEARCHING FOR THE CAUSES OF ANAPLASTIC LARGE CELL LYMPHOMA	5
Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia	5
LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia	5
MDS BIOLOGY AND PATHOGENESIS - IMMUNE DEREGULATION / INFLAMMATION	4
PROGNOSIS - PREDICTIVE FACTORS OF RESPONSE TO TREATMENT	4
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia	4

ALK INIHIBITOR THERAPY IN ALCL	4
Growth and dormancy control of myeloma cells by mesenchymal stem cells	4
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: BEYOND DDX41: DDH AND DHX HELICASES ARE MUTATED IN MDS	4
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB	4
VARYING OUTCOMES OF MATURE T AND NK LYMPHOMA IN PEDIATRIC AND ADOLESCENT/YOUNG ADULT PATIENTS: A SINGLE INSTITUTION EXPERIENCE	4
Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation	4
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS	4
RAPID FIRE SESSION 01	4
SPECIFIC DISEASE ENTITIES - HEREDITARY MDS INCLUDING PREDISPOSITION SYNDROMES	4
Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT)	4
Editorial Board	4
Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma	4
CHARACTERIZING THROMBOSIS IN CHILDREN & ADOLESCENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA	4
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE	4
RITUXIMAB CLEARANCE IN PEDIATRIC PATIENTS WITH MAATURE B-CELL NON-HODGKIN LYMPHOMA	4
Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era	4
Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML),	4
NAP1L5 promotes epithelial–mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia	4
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART II	4
MDS BIOLOGY AND PATHOGENESIS - CLONAL DIVERSITY & EVOLUTION	4
Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WIT	4
Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy	4
PDGFRβ DRIVES PROGRESSION BY ONCOGENE TRANSCRIPTION THROUGH STAT3/STAT5 HYPERACTIVATION IN ALCL	4
MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12	4
PEDIATRIC AND YOUNG ADULT ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA GENETICALLY DIFFERS FROM THE ADULT COUNTERPART	4
Erratum to ‘Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system’ [Leukemia Research 112C	4
Editorial Board	4
Real-World Treatment Patterns and Clinical Outcomes of Patients with Treatment-naïve and Relapsed/Refractory Diffuse Large B-cell Lymphoma in the United States	4
Editorial Board	4
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): MAMMALIAN DIAPHANOUS-RELATED FORMIN 1 IS REQUIRED FOR MAINTAINING HEMATOPOIETIC STEM CELL QUIESCENCE AND SURVIVAL VIA REGU	3
Editorial Board	3
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia	3
Improved resolution of phenotypic subsets in human T-ALL by incorporation of RNA-seq based developmental profiling	3
PROGNOSIS - PROGNOSTIC FACTORS OF OUTCOME AND RISK ASSESSMENT	3
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas	3
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine	3
Topic: AS01-Diagnosis/AS01a-Cytomorphology: NON-INVASIVE WEB-BASED DIAGNOSTIC ALGORITHM FOR MDS – MODEL PERFORMANCE AND VALIDATION	3
Editorial Board	3
Topic: AS01-Diagnosis/AS01a-Cytomorphology: AUTOMATED DIGITAL TOOL FOR MDS AND MDS/MPN CLASSIFICATION USING WHO AND ICC: INTERNATIONAL GUIDELINES WORKING GROUP ON MDS DIAGNOSIS, PROGNOSIS, AND GERMLIN	3
Proposal and clinical application of molecular genetic risk scoring system, “MRplus”, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre	3
Clonal hematopoiesis: Molecular and clinical implications	3
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ROUTINE INFLAMMATORY MARKERS ARE ELEVATED IN MYELODYSPLASTIC SYNDROMES AT PRESENTATION	3
Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review	3
MOLECULAR GENETICS ANALYSIS OF B-CELL PRECURSOR LYMPHOMA IN PEDIATRIC AND ADOLESCENT PATIENTS REVEALS HIGH FREQUENCY OF KMT2A TRANSLOCATIONS	3
SPECIFIC DISEASE ENTITIES - MDS WITH RING SIDEROBLASTS/SF3B1	3
TARGETING PRIMARY CENTRAL NERVOUS SYSTEM B CELL LYMPHOMA IgH CLONOTYPES USING NOVEL RNA-NPs	3
GLOFITAMIB PLUS R-ICE (RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE) OR AS MONOTHERAPY IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL): ANALYSIS FROM THE iMAT	3
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE	3
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort	3
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion	3
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria	3
GUIDED POSTER VIEWING SESSION 1: THERAPY - PART II	3
CLINICAL SPECTRUM OF PRECURSOR B-CELL LYMPHOBLASTIC MALIGNANCIES: A LARGE COHORT STUDY OF 364 PEDIATRIC PATIENTS	3
Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients	3
Central nervous system involvement in adult acute myeloid leukemia patients	3
Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms	3
BCR EXPRESSION IN BURKITT LYMPHOMA: NEW INSIGHT IN MUTATIONAL LANDSCAPE	3
The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis	3
Effects of conventional interventions on early-stage primary cutaneous marginal zone lymphoma: A population-based study	3
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MUTATIONS OF SF3B1 GENE AND ITS SIGNIFICANCE ON PATIENTS WITH MYELODYSPASTIC SYNDROMES (MDS)	3
Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study	3
CLINICAL OUTCOME PREDICTION IN PEDIATRIC PRIMARY MEDIASTINAL B CELL LYMPHOMA – A JOINT BFM AND INTER-B-NHL RITUX 2010 ANALYSIS	3
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy	3
PEDIATRIC INFRADIAPHRAGMATIC HODGKIN’S LYMPHOMA: A UNIQUE IDENTITY	3
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)	3
AN UNUSUAL PRESENTATION OF A RARE PEDIATRIC DISEASE	3
Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy	3
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution	3
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPEN	3
Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?	3
SYSTEMIC EPSTEIN-BARR VIRUS-POSITIVE T-CELL LYMPHOMA OF CHILDHOOD: A CASE SERIES AND REVIEW OF THE LITERATURE	3
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN THE TREATMENT OF MDS PATIENTS. A SINGLE CENTER EXPERIENCE	3
COMBINATIONAL NATAURAL KILLER (NK) CELL-BASED IMMUNOTHERAPY TO CIRCUMVENT RESISTANCE IN RITUXIMAB-RESISTANT BURKITT LYMPHOMA (BL)	3
A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis	3
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial	3
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience	3
EPSTEIN-BARR VIRUS ORCHESTRATE THE TUMOR MICROENVIRONMENT OF BURKITT LYMPHOMA	3
Multiple cells of origin in common with various types of mouse N-Myc acute leukemia	3
CLINICAL CHARACTERISTICS AND TREATMENT EVALUATION OF DIFFUSE LARGE B-CELL LYMPHOMA IN CHINESE CHILDREN AND ADOLESCENTS: A MULTICENTER CLINICAL STUDY OF CHINA-NET CHILDHOOD LYMPHOMA GROUP B-NHL-2017	3
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions	3
Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia	2
TREATMENT - CURRENT TREATMENT OPTIONS - HIGHER RISK MDS	2
PLENARY SESSION 1: MOLECULAR PATHOGENESIS OF MDS	2
Topic: AS08-Treatment/AS08i-observational studies: ALLOGENEIC ADOPTIVE CELLULAR IMMUNOTHERAPY FOR MYELODYSPLASTIC SYNDROME AND ITS EFFECT ON TRISOMY OF CHROMOSOME 8	2
BCR-ABL is enriched in S- and G2-cell cycle phases	2
Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest	2
GERMLINE DDX41 MUTATIONS : CLINICAL IMPACT & ETHNIC DIVERSITY	2
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): CORRECTING DYSREGULATED IRON METABOLISM IN A MURINE MODEL OF MDS	2
A UK POPULATION-BASED STUDY OF NON-HODGKIN LYMPHOMA IN ADOLESCENTS AND YOUNG ADULTS: TREATMENT-RELATED OUTCOMES FOR DIFFUSE LAREG B-CELL	2
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: THE IMPACT OF CHIP ON CHEMOTHERAPY-RELATED OUTCOMES AND CLONAL DYNAMICS IN OLDER LYMPHOMA PATIENTS	2
GUIDED POSTER VIEWING SESSION 2: FUNDAMENTAL	2
DIAGNOSIS - FLOW CYTOMETRY	2
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS	2
CURRENT STATUS OF MOLECULAR ANALYSIS OF MRD IN MDS	2
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax	2